pharmaphorum June 29, 2022
The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. However, this picture of recovery hides a less positive trend – non-COVID innovative launches from 2020 onwards, have, with certain exceptions, under-performed pre-pandemic benchmarks of launch sales performance in the major countries in the market – that is, the US, EU4+UK, China and Japan.
The scope of the problem
Non-COVID prescription medicines didn’t stop launching during the pandemic — approvals by both the FDA and the EMA were, in fact...
Today's Sponsors
Today's Sponsor